ClinicaliQ Trial Snapshot
- Efficacy and Safety Study of OATD-01 in Patients With Active Pulmonary Sarcoidosis — Recruiting • Phase II • Respiratory / COPD / Asthma • NCT06205121.
- OATD-01 is being tested as a potential therapeutic agent for active pulmonary sarcoidosis in a Phase 2 randomized controlled trial, with assessment of efficacy, safety, tolerability, and pharmacodynamic/pharmacokinetic profiles across multiple UK healthcare centres.
- Eligible patients have active pulmonary sarcoidosis requiring treatment; the adaptive trial design allows for optimization of dosing and patient selection as data accumulates during the study period.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
This is a Phase 2, randomized, double-blind, placebo-controlled, adaptive, multicenter study to evaluate the efficacy, safety, tolerability, Pharmacodynamics (PD), and Pharmacokinetics (PK) of OATD-01 in the treatment of subjects with active pulmonary sarcoidosis.
Eligibility Snapshot
- : * Male and female subjects with active symptomatic pulmonary sarcoidosis, (definite diagnosis of active pulmonary sarcoidosis per ATS guidelines) * Treatment-naïve or previously treated (no recruitment cap) * Parenchymal pulmonary involvement on [18F]FDG PET/CT
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.